Skip to content
RKWD
ROCKWOOD RESEARCH · A CORPORATE FILINGS WEBSITE|STRAIGHT FROM THE SOURCE · SEC EDGAR|SPONSOREDYour message on this tape — bid on the Rockwood Ad Exchange · Rockwood Ad Exchange|
Rockwood Research
…

TVTX

Travere Therapeutics, Inc.

Pharmaceutical Preparations · SIC 2834CIK 1438533Held by 5 tracked managersEDGAR filings ↗10-K/10-Q ↗

SHARE:XLINKEDINEMAIL
Revenue FY2025
$491.0M
Net Income FY2025
$(26.0M)
EPS (Basic, as reported)
$-0.29
Net Margin FY2025
-5.2%
ROE FY2025
-22.2%
Total Equity
$115.0M
Shares Out
94M
Business description

Travere Therapeutics, Inc. — Pharmaceutical Preparations. Figures are as reported in each year's original 10-K via SEC EDGAR XBRL company facts (FY2011–FY2025; structured XBRL data begins around 2008). Market-price metrics are not part of EDGAR data.

Annual (fiscal years, as reported)USD millions
i
default rows · click any row to chart itRevenue: 134 → 491 +15.5% CAGR
Fiscal yearFY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Revenue134155164175198227212145233491
Cost of revenue(5)(4)(6)(5)(6)(7)(8)(11)(8)(10)
Research & development(71)(78)(124)(141)——(7)———
Selling, general & administrative(93)(101)(104)(129)(136)(150)(220)(266)(264)(337)
General & administrative——————————
Total operating expenses(192)(209)(244)(313)(374)(389)(479)(533)(557)(554)
Operating income(58)(54)(80)(137)(176)(162)(267)(388)(324)(63)
Interest expense(1)(1)(10)(19)(19)(20)(11)(11)(11)(11)
Interest & investment income—3510526221813
Other income (expense), net1(5)(22)(9)(13)(18)(12)12314
Pre-tax income(58)(58)(102)(146)(189)(180)(278)(376)(321)(49)
Income tax expense(10)(1)(1)0(19)0000(1)
Net income(48)(60)(103)(146)(169)(180)(278)(111)(322)(26)
EPS — basic($1.29)($1.54)($2.54)($3.46)($3.56)($3.01)($4.37)($1.50)($4.08)($0.29)
EPS — diluted($1.29)($1.54)($2.54)($3.46)($3.56)($3.01)($4.37)($1.50)($4.08)($0.29)
Shares outstanding — basic (M)37394042486064747989
Shares outstanding — diluted (M)38394042486064747989

Showing the latest 10 of 15 fiscal years.

Source: SEC EDGAR XBRL company facts — figures as reported in each period's original filing (structured data begins ~2008). EPS and other per-share figures are as reported and are not adjusted for later stock splits; a ⚑ marks a period where the reported share count changed by a large factor. Dollar figures in millions unless per-share. Line items a company never reports are omitted. Where a filer switched XBRL concepts, the successor concept is used and definitions can differ slightly (e.g. cash may include restricted cash; banks' revenue is net of interest expense; cost of revenue may exclude D&A; net income may be the amount available to common stockholders; debt issued/repaid may be net of issuance costs or include finance-lease obligations — each only where the original concept stopped being reported). Click a period header to open that period's source filing on EDGAR.